.png)
Since 1998, SYNAGIS has remained at the forefront of the battle to prevent serious RSV disease1
Currently the only humanized recombinant monoclonal antibody for the prevention of serious RSV disease requiring hospitalisation in high-risk infants1-3
THE FIRST AND ONLY PROPHYLAXIS AGAINST RSV 1-3
OVER 20 YEARS OF CLINICAL EXPERIENCE1
PRESCRIBED IN MORE THAN 70 MARKETS4
INDICATIONS
SYNAGIS is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by RSV in children at high risk for RSV disease2:
Children born at ≤35 wGA and <6 months of age at the onset of the RSV season
Children under 2 years of age and requiring treatment for bronchopulmonary dysplasia (BPD) within the last 6 months.
Children under 2 years of age born with haemodynamically significant congenital heart disease (HSCHD)
SYNAGIS is a seasonal immunoprophylaxis, not a vaccine, and does not induce the production of endogenous anti-RSV antibodies in infants2
MECHANISM OF ACTION
The video demonstartes Respiratory Syncytial Virus, its structure, mode of transmission, high risk infants and Mechanism of Action of SYNAGIS.
For full safety and prescribing information, please see the SYNAGIS Summary of Product Characteristics (SmPC).
RSV = respiratory syncytial virus; wGA = weeks gestational age
References: 1. Resch B. Hum Vaccin Immunother. 2017;13(9):2138-2149. 2. SYNAGIS (palivizumab). Summary of Product Characteristics. 3. Goldstein M, et al. Neonatology Today. 2017;12(10):1-27. 4.Data on File. AstraZeneca. Veeva Approval ID: REF-94356.